Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference
Rezolute (Nasdaq: RZLT), a late-stage biopharmaceutical company focused on developing transformative therapies for rare diseases, has announced its participation in the Guggenheim SMID Cap Biotech Conference. The conference is scheduled for February 5-6, 2025, in New York City.
The company's management team will be available for one-on-one meetings with investors throughout the conference. Interested investors can arrange meetings through their Guggenheim representatives.
Rezolute (Nasdaq: RZLT), un'azienda biofarmaceutica in fase avanzata focalizzata sullo sviluppo di terapie transformative per malattie rare, ha annunciato la sua partecipazione al Guggenheim SMID Cap Biotech Conference. La conferenza si terrà dal 5 al 6 febbraio 2025, a New York City.
Il team di gestione dell'azienda sarà disponibile per incontri individuali con gli investitori durante l'intera conferenza. Gli investitori interessati possono programmare incontri tramite i loro rappresentanti di Guggenheim.
Rezolute (Nasdaq: RZLT), una empresa biofarmacéutica en etapa avanzada centrada en el desarrollo de terapias transformadoras para enfermedades raras, ha anunciado su participación en la Guggenheim SMID Cap Biotech Conference. La conferencia está programada para el 5 y 6 de febrero de 2025, en la ciudad de Nueva York.
El equipo de gestión de la compañía estará disponible para reuniones individuales con inversores durante toda la conferencia. Los inversores interesados pueden coordinar reuniones a través de sus representantes de Guggenheim.
Rezolute (Nasdaq: RZLT)는 희귀 질환을 위한 혁신적인 치료법 개발에 중점을 둔 후기 단계의 생명공학 회사로, Guggenheim SMID Cap Biotech Conference에 참여한다고 발표했습니다. 이 회의는 2025년 2월 5일부터 6일까지 뉴욕에서 개최됩니다.
회사의 경영진은 회의 전반에 걸쳐 투자자와의 일대일 미팅을 위해 대기하고 있습니다. 관심 있는 투자자는 Guggenheim의 대표자를 통해 미팅을 조율할 수 있습니다.
Rezolute (Nasdaq: RZLT), une entreprise biopharmaceutique en phase avancée axée sur le développement de thérapies transformantes pour des maladies rares, a annoncé sa participation à la Guggenheim SMID Cap Biotech Conference. La conférence est prévue pour le 5 et 6 février 2025, à New York.
L'équipe de direction de l'entreprise sera disponible pour des réunions individuelles avec les investisseurs tout au long de la conférence. Les investisseurs intéressés peuvent organiser des réunions par l'intermédiaire de leurs représentants Guggenheim.
Rezolute (Nasdaq: RZLT), ein biopharmazeutisches Unternehmen in der späten Entwicklungsphase, das sich auf die Entwicklung transformierender Therapien für seltene Krankheiten konzentriert, hat seine Teilnahme an der Guggenheim SMID Cap Biotech Conference bekannt gegeben. Die Konferenz ist für den 5. und 6. Februar 2025 in New York City geplant.
Das Management-Team des Unternehmens wird während der gesamten Konferenz für Einzelgespräche mit Investoren zur Verfügung stehen. Interessierte Investoren können Meetings über ihre Vertreter von Guggenheim arrangieren.
- None.
- None.
REDWOOD CITY, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, today announced that management will participate in the Guggenheim SMID Cap Biotech Conference, taking place February 5-6, 2025, in New York City.
Management will be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with the Rezolute management team should contact their Guggenheim representative.
About Rezolute, Inc.
Rezolute is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, is designed to treat all forms of HI and has shown substantial benefit in clinical trials and real-world use for the treatment of congenital HI and tumor HI. For more information, visit www.rezolutebio.com.
Contact:
Rezolute, Inc.
Christen Baglaneas
cbaglaneas@rezolutebio.com
508-272-6717
FAQ
When is Rezolute (RZLT) participating in the Guggenheim SMID Cap Biotech Conference 2025?
How can investors meet with Rezolute (RZLT) management at the Guggenheim Conference?
What is the focus of Rezolute's (RZLT) drug development pipeline?
Where will the Guggenheim SMID Cap Biotech Conference featuring RZLT be held?
